Latest research and treatment of advanced-stage epithelial ovarian cancer.
Latest research and treatment of advanced-stage epithelial ovarian cancer.
复制标题
DOI：
10.1038/nrclinonc.2013.5
复制
发表时间：
2013-04
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
卵巢癌的自然史仍然以晚期表现、转移性大体积疾病负担和死亡率统计停滞为特征，尽管有大量的药物开发。强有力的临床研究，特别是对主要治疗手术目标和辅助治疗的修改，正在增加中位无进展生存期和总生存期，尽管治愈率仅受到适度影响。维持治疗有希望，但研究尚未确定可以影响生存的药物和/或策略。复发性疾病在很大程度上是一种无法治愈的状态;然而，目前采用选定的手术、联合和靶向治疗以及研究方案进行的干预正在影响无进展生存期。卵巢癌是一种多样性和基因组复杂的疾病，引起了全球的关注。合理的调查必须平衡高发现率与滞后的临床调查和有限的患者资源。然而，医疗设备的增长为患有这种疾病的患者提供了前所未有的机会。本综述介绍并回顾了被称为上皮性卵巢癌的疾病谱的当代管理，并介绍了临床研究的方向和早期结果。
The natural history of ovarian cancer continues to be characterized by late-stage presentation, metastatic bulky disease burden and stagnant mortality statistics despite prolific drug development. Robust clinical investigation, particularly with modifications to primary treatment surgical goals and adjuvant therapy are increasing median progression-free and overall survival, although the cure rates have only modestly been affected. Maintenance therapy holds promise, but studies have yet to identify an agent and/or strategy that can affect survival. Recurrent disease is largely an incurable state; however, current intervention with selected surgery, combination and targeted therapy and investigational protocols are impacting progression-free survival. Ovarian cancer is a diverse and genomically complex disease, which commands global attention. Rational investigation must balance the high rate of discovery with lagging clinical investigation and limited patient resources. Nevertheless, armamentarium growth offers unprecedented opportunities for patients suffering with this disease. This Review presents and reviews the contemporary management of the disease spectrum termed epithelial ‘ovarian’ cancer and introduces the direction and early results of clinical investigation.
登录
查看更多内容
影响因子：
45.3
作者：
Ferrandina, Gabriella;Ludovisi, Manuela;Scambia, Giovanni
通讯作者：
Scambia, Giovanni
影响因子：
4.7
作者：
Chi, Dennis S.;Musa, Fernanda;Barakat, Richard R.
通讯作者：
Barakat, Richard R.
影响因子：
10.3
作者：
du Bois, A;Lück, HJ;Pfisterer, J
通讯作者：
Pfisterer, J
影响因子：
4.7
作者：
Coleman RL;Brady WE;McMeekin DS;Rose PG;Soper JT;Lentz SS;Hoffman JS;Shahin MS
通讯作者：
Shahin MS
影响因子：
158.5
作者：
Burger, Robert A.;Brady, Mark F.;Liang, Sharon X.
通讯作者：
Liang, Sharon X.